WuXi Biologics (Cayman) Inc. (BKK:WUXI06)

Market Cap	524.26B
Revenue (ttm)	90.92B
Net Income (ttm)	19.02B
Shares Out	n/a
EPS (ttm)	4.48
PE Ratio	27.56
Forward PE	22.06
Dividend	n/a
Ex-Dividend Date	n/a

Volume	92,567
Average Volume	126,762
Open	3.200
Previous Close	3.240
Day's Range	3.180 - 3.280
52-Week Range	3.160 - 4.020
Beta	n/a
RSI	41.01
Earnings Date	Mar 20, 2026

About WuXi Biologics

WuXi Biologics (Cayman) Inc., an investment holding company, provides end-to-end solutions and services for biologics discovery, development, and manufacturing for biologics industry in the People’s Republic of China, North America, Europe, Singapore, Japan, South Korea, and Australia. It operates through two segments: Biologics and XDC. The company provides a suite of solutions for biologic discovery, from concept to IND, that seamlessly transits to CMC and downstream process development through its contract research, development, and manufact...

• Industry: Commercial Physical and Biological Research
• Founded: 2014
• Employees: 12,575
• Stock Exchange: Stock Exchange of Thailand
• Ticker Symbol: WUXI06

Financial Performance

In 2024, WuXi Biologics's revenue was 18.68 billion, an increase of 9.63% compared to the previous year's 17.03 billion. Earnings were 3.36 billion, a decrease of -1.28%.

Financial numbers in CNY